Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-cash Items (2016 - 2020)

United Therapeutics' Non-cash Items history spans 10 years, with the latest figure at $43.5 million for Q1 2020.

  • For Q1 2020, Non-cash Items rose 12.69% year-over-year to $43.5 million; the TTM value through Mar 2020 reached $43.5 million, up 12.69%, while the annual FY2019 figure was $90.1 million, 175.54% up from the prior year.
  • Non-cash Items for Q1 2020 was $43.5 million at United Therapeutics, down from $90.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $176.7 million in Q4 2016 and bottomed at $28.4 million in Q3 2019.
  • The 5-year median for Non-cash Items is $61.5 million (2016), against an average of $76.4 million.
  • The largest YoY upside for Non-cash Items was 3172.22% in 2016 against a maximum downside of 82.65% in 2016.
  • A 5-year view of Non-cash Items shows it stood at $176.7 million in 2016, then plummeted by 42.39% to $101.8 million in 2017, then plummeted by 67.88% to $32.7 million in 2018, then surged by 175.54% to $90.1 million in 2019, then plummeted by 51.72% to $43.5 million in 2020.
  • Per Business Quant, the three most recent readings for UTHR's Non-cash Items are $43.5 million (Q1 2020), $90.1 million (Q4 2019), and $28.4 million (Q3 2019).